ArticleThe Journal of biological chemistry2007
Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.
Article in The Journal of biological chemistry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 51 citations in OpenAlex.
- Inhibition of phospholipase D2 augments histone deacetylase inhibitor-induced cell death in breast cancer cells.Biological research · 2020Article
- Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy.Cancers · 2019Review
- p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death.International journal of molecular sciences · 2019Review
- Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells.OncoTargets and therapy · 2018Article
- Acetylation is essential for nuclear heme oxygenase-1-enhanced tumor growth and invasiveness.Oncogene · 2017Article
- Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity.Cell chemical biology · 2017Article
- The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and nNav1.5 expression in breast cancer.Cancer cell international · 2017Article
- Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.BMC cancer · 2016Article
- The Histone-Deacetylase-Inhibitor Suberoylanilide Hydroxamic Acid Promotes Dental Pulp Repair Mechanisms Through Modulation of Matrix Metalloproteinase-13 Activity.Journal of cellular physiology · 2016Article
- Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients.Oncoimmunology · 2016Article
- Metal-dependent Deacetylases: Cancer and Epigenetic Regulators.ACS chemical biology · 2016Review
- Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.British journal of pharmacology · 2015Article
- New and emerging HDAC inhibitors for cancer treatment.The Journal of clinical investigation · 2014Review
- ABCD2 is a direct target of β-catenin and TCF-4: implications for X-linked adrenoleukodystrophy therapy.PloS one · 2013Article
- Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.ISRN dermatology · 2013Article
- Histone deacetylases and cancer.Molecular oncology · 2012Review
- PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-κB- and HDAC1-mediated expression and activation of uPA.Journal of cell science · 2012Article
- Article
- Tissue factor pathway inhibitor-2 inhibits the growth and invasion of hepatocellular carcinoma cells and is inactivated in human hepatocellular carcinoma.Oncology letters · 2011Article
- Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors.Biochemical and biophysical research communications · 2011Article
Corrections and comments
- Retraction · 2020-09-01Concerns/Issues about Data · Duplication of/in Image ·
- Retracted
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Histone acetylation plays an important role in chromatin remodeling and gene expression. The molecular mechanisms involved in differential regulation of urokinase plasminogen activator (uPA) gene expression are not fully understood. In this study, we investigated whether histone deacetylation was involved in repression of uPA expression in human cancer cells. Induction of uPA expression by histone deacetylase (HDAC) inhibitors trichostatin A (TSA), sodium butyrate, and scriptaid was observed in all three different types of human cancer cells examined. Chromatin immunoprecipitation assays showed that the induction of uPA expression by TSA was accompanied by a remarkable increase of acetylation of histones H3 and H4, which are associated with the uPA promoter region in human cancer cells. These results were further substantiated by the findings of a restriction enzyme accessibility assay and TSA-stimulated uPA promoter activity through the inhibition of HDAC activity. In vitro Matrigel invasion assays showed that induction of uPA expression by HDAC inhibitors in human cancer cells resulted in a significant increase of cancer cell invasion. Furthermore, HDAC1 knockdown by small interference RNA stimulated uPA expression and cancer cell invasion. In conclusion, this study demonstrates the important role of histone modifications in regulating uPA gene expression and raises a possibility that the use of HDAC inhibitors in patients as cancer therapy may paradoxically establish metastasis through up-regulation or reactivation of uPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.